Quest Diagnostics Incorporated Earnings Recaps
Q2 2026
Jul 25, 2026
The 8.6% stock gain reflects investor approval of Quest Diagnostics’ broad-based revenue growth and strong adjusted EPS increase, supported by robust demand across clinical, hospital, and consumer segments and raised full-year guidance.
Key takeaways
- Revenues grew over 10% year-over-year, driven by physician, hospital, and consumer health demand, including collaborations with Corewell Health and Fresenius Medical Care.
- Adjusted diluted EPS increased by more than 19%, bolstered by automation and AI in lab operations improving quality and productivity.
- Double-digit revenue growth was noted in hospital partnerships, consumer wellness services (including new thyroid testing), and several advanced diagnostics areas such as cardiometabolic, autoimmune, brain health, and oncology.
- The company expanded its oncology test access with New York State approval of Haystack MRD and integration with Flatiron Health’s Onco EMR platform, enabling broader commercial reach.
- Management raised full-year guidance, signaling confidence in sustained demand driven by demographic and technological trends.
Q1 2026
Apr 21, 2026
Quest Diagnostics delivered a robust first quarter with over 9% organic revenue growth and a 13% increase in adjusted EPS, driven by broad-based demand and operational efficiencies.
Key takeaways
- Organic revenue growth nearly entirely fueled by clinical innovations, new clinical areas like dialysis testing, and strategic collaborations.
- Double-digit revenue growth in hospital channels, especially through lab solutions with Corewell Health, complemented by expanding partnerships and new lab openings.
- Consumer health revenue surged, supported by strong repeat customer engagement and expanding lab insights integrated into digital health platforms.
- Continued leadership in diagnostics for Alzheimer's and cardiometabolic markers, reflecting successful innovation such as the AD-Detect blood test and new biomarker guidelines.
- Management raises full-year revenue and EPS guidance, reflecting confidence in sustained momentum and strategic execution.